0000950170-24-057926.txt : 20240510 0000950170-24-057926.hdr.sgml : 20240510 20240510165704 ACCESSION NUMBER: 0000950170-24-057926 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Struthers Richard Scott CENTRAL INDEX KEY: 0001746298 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 24935799 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-05-08 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001746298 Struthers Richard Scott C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 true true false false President & CEO true Common Stock 2024-05-08 4 M false 107448 9.28 A 364933 D Common Stock 2024-05-08 4 S false 107448 49.40 D 257485 D Common Stock 570805 I By Family Trust 1 Common Stock 110000 I By Family Trust 2 Common Stock 110000 I By Family Trust 3 Common Stock 110000 I By Family Trust 4 Common Stock 1000 I By Spouse Stock Option (Right to Buy) 9.28 2024-05-08 4 M false 107448 0 D 2028-05-24 Common Stock 107448 16342 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023. The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-05-10